Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$14.6M | -$28.4M | -$30.9M | -$22.9M | -$11.3M | -$12.6M |
| Net income | -$16.2M | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M |
| EPS (diluted) | -$0.67 | -$1.16 | -$0.83 | -$6.54 | -$2.86 | -$2.93 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.34M | -$12.8M | -$18.9M | -$15.8M | -$9.56M | -$5.93M |
| Capital expenditures | $95.2K | $249K | $250K | $73.6K | — | — |
| Free cash flow | -$8.43M | -$13.1M | -$19.1M | -$15.8M | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.69M | $38.9M | $19.6M | $3.37M | $4.58M | $13.4M |
| Total assets | $4.56M | $40.2M | $21.5M | $4.55M | $5.72M | $14.2M |
| Shareholders' equity | -$53.9M | $23.8M | -$401K | -$18.1M | -$19.6M | -$14.2M |
| Retained earnings | -$52.7M | -$82.9M | -$111M | -$133M | -$144M | -$157M |
| Shares (wtd avg diluted) | — | 26.0M | 33.7M | 3.44M | 3.77M | 4.27M |
Every figure is extracted from MiNK Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.